Skip to content
  • Digital Replacement: Creativity, Connection, and the Role of AI

    Digital Replacement: Creativity, Connection, and the Role of AI

    As long as I can remember, I’ve been an artist. For me, art is a way to connect with others, make sense of life, express ideas, and share stories. Over time, I’ve developed an appreciation for the history of art and the many ways humanity has created and utilized it.
  • Supporting Innovation in Connecticut: A Partnership of Progress with Connecticut Innovations

    As a Connecticut-based company, we're not just located in the state; we are an integral part of its vibrant ecosystem of innovation and progress. Our pride in being a Connecticut company runs deep, fueled by the opportunities to collaborate with remarkable inventors, scientists, and entrepreneurs.
  • XVIVO Welcomes Medical Illustrator Alisa Brandt

    XVIVO is thrilled to announce its newest hire, Alisa Brandt. A Master of Arts graduate of John Hopkins University School of Medicine in Baltimore, Maryland, Alisa has extensive experience in medical and biological illustration, animation and fine art.
  • The Cellspan implant in action

    Start-up with Style: Launch your Visuals with XVIVO

    As the saying goes, a picture is worth a thousand words. Start-up pharmaceutical and biotech companies often need to create illustrations, investigational candidate images, and animations to provide rich scientific detail on a disease state, a process, or a mechanism of action for their website, for presentations, and for printed materials. XVIVO Scientific Animation is …
  • Protac, an experimental treatment, uses the body's own protein disposal system.

    Illustrating the Unconventional: PROTAC™ Technology for Disease Therapy

    XVIVO, in collaboration with Wyant Simboli and their client, Arvinas Inc., helped communicate the unconventional mechanism of action for a new class of drugs that engage the body’s own protein disposal system to target cancers and other difficult-to-treat diseases. PROTAC™ PLATFORM Arvinas’ approach is to tag a protein implicated in a disease with their proprietary Proteolysis-Targeting Chimera, …